Amgen
Bristol Myers Squibb Scoops Up Rights to BridgeBio's SHP2 Inhibitor
BridgeBio has exclusively licensed BBP-398 to BMS for $90 million upfront, extending a prior collaboration to evaluate the agent with Opdivo in KRAS-mutated solid cancers.
Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials
MPAACT members will share trial data, aiming to standardize measurable residual disease as a surrogate endpoint for overall survival and speed up drug development. Â
Amgen Q1 Revenues Increase 6 Percent With Strong Growth in Lumakras Sales
The firm is anticipating multiple clinical trial readouts for the KRAS G12C inhibitor in 2022, which recorded $62 million in revenues in the first quarter.
Novartis Enters KRAS G12C Space With Positive Phase I/II Data in Lung, Colorectal Cancer
Novartis' JDQ443 showed a 45 percent response rate in advanced KRAS G12C-mutant non-small cell lung cancer patients.
In a biomarker analysis, the researchers found KEAP1 co-mutations and low tumor mutation burden may be predictive of outcomes on Lumakras.